Coverage Initiated on U.S.-Based Precision Therapy Developer
Source: Streetwise Reports  (10/8/19)
The key reasons this story is compelling are given in an H.C. Wainwright & Co. report. More >

Akcea Therapeutics Inks Worldwide Licensing Deal with Pfizer for Investigative Antisense Therapy, Shares Up 30%
Source: Streetwise Reports  (10/7/19)
Akcea Therapeutics' shares are trading 30% higher today on news that it has entered into a worldwide exclusive licensing agreement with Pfizer for AKCEA-ANGPTL3-LRx used in the treatment of patients with cardiovascular and metabolic diseases. More >

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial
Source: Streetwise Reports  (10/3/19)
This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection. More >

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'
Source: Streetwise Reports  (9/30/19)
The latest clinical trial results are dissected in a ROTH Capital Partners report. More >

Dova Pharma Shares Rise 38% on Swedish Firm Takeover Offer
Source: Streetwise Reports  (9/30/19)
Shares of Dova Pharmaceuticals opened 38% higher today on news that the firm will be acquired by Swedish Orphan Biovitrum. The deal is reportedly valued at $915 million or $29/share. More >

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study
Source: Streetwise Reports  (9/27/19)
Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. More >

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results
Source: Streetwise Reports  (9/26/19)
Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. More >

Shares Rise as The Medicines Company Reports Positive Topline Results from Two Phase 3 Cholesterol Trials
Source: Streetwise Reports  (9/25/19)
The Medicines Company's shares are trading 8.5% higher today after the firm reported positive results from two phase 3 studies for inclisiran, one for familial hypercholesterolemia, which leads to high levels of LDL-C, and one for atherosclerotic cardiovascular disease. More >

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results
Source: Streetwise Reports  (9/25/19)
The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. More >

Analyst: Acquisition by Colorado-Based Specialty Pharma 'Could Bolster Revenue 400%'
Source: Streetwise Reports  (9/24/19)
The benefits and terms of the agreement are outlined in a Ladenburg Thalmann report. More >

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial
Source: Streetwise Reports  (9/24/19)
Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. More >

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study
Source: Streetwise Reports  (9/23/19)
Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. More >

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation
Source: Streetwise Reports  (9/20/19)
Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Products for Human Use also adopted a positive opinion for Dupixent in a third indication. More >

Biopharma Reports Positive Data from Alcoholic Hepatitis Study
Source: Streetwise Reports  (9/18/19)
These results are from the recently completed clinical trial of the firm's lead drug candidate. More >

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor
Source: Streetwise Reports  (9/18/19)
The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. More >

Alder BioPharmaceuticals Shares Surge 80% on Acquisition News
Source: Streetwise Reports  (9/16/19)
Shares of migraine treatment research firm Alder BioPharmaceuticals opened 84% higher today after the company announced that it has agreed to be acquired by H. Lundbeck for $1.95 billion. More >

Fibrocell Science Shares Rise 60% on Acquisition News
Source: Streetwise Reports  (9/13/19)
Fibrocell Science's shares are trading up 60% today after the company announced that it agreed to be acquired by Castle Creek Holdings for $63.3 million, or $3.00 per share. More >

Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs
Source: Streetwise Reports  (9/12/19)
Shares of Moderna Inc. traded up double-digits as the firm announced results from its Phase 1 CMV Vaccine Study as well as its Phase 1 data for mRNA-1944 encoding for antibody against the chikungunya virus. More >

Company Develops Cannabinoid-Measuring Process for Liquids
Source: Streetwise Reports  (9/11/19)
This proprietary method ensures the firm meets the requirements for its cannabis-containing beverages and oils. More >

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute
Source: Streetwise Reports  (9/11/19)
Lexicon Pharmaceuticals shares traded higher by more than 30% today after the company announced termination of its alliance with Sanofi SA and a $260 million settlement over its diabetes drug Zynquista. More >

Biopharma Makes Licensing Deal for Therapeutic Rights in Japan
Source: Streetwise Reports  (9/11/19)
The company's reasons for the transaction and expected short-term, stock-moving events are provided in a ROTH Capital Partners report. More >

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%
Source: Streetwise Reports  (9/11/19)
This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. More >

Mallinckrodt Shares Up 60% as It Announces Sale of Unit
Source: Streetwise Reports  (9/10/19)
Shares of Mallinckrodt Plc are trading more than 60% higher today on news that the company is selling its CDMO subsidiary BioVectra Inc. to H.I.G. Capital for $250 million. More >

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results
Source: Streetwise Reports  (9/9/19)
Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. More >

Technology License Triggers $10 Million Milestone Payment for Biopharma
Source: Streetwise Reports  (9/9/19)
This is the first of many such potential payments under the related agreement. More >